natgillin/translations-raw huggingface dataset:
This condition usually does not occur until a few months after onset of treatment.
Stanje se ponavadi pojavi šele nekaj mesecev po začetku zdravljenja.
Antiretroviral prophylaxis, the same medications as given to the mother, was given to the new-born infant within 36 hours of delivery and continued for 6 weeks.
Novorojenčki so dobivali protiretrovirusno profilakso z istim zdravilom, kot ga je jemala mati; prvič so ga dobili v 36 urah po rojstvu in so ga prejemali 6 tednov.
After reconstitution, store the prepared oral solution in a refrigerator (2°C - 8°C) for 30 days.
2 leti Po rekonstituciji pripravljeno peroralno raztopino shranjujte v hladilniku (2 °C - 8 °C) največ 30 dni.
Although there are insufficient data to recommend a specific dosage adjustment of Zerit in this patient population, a reduction in the dose and/or an increase in the interval between doses proportional to the reduction for adults should be considered.
Priporočil za specifično prilagoditev odmerkov zdravila Zerit pri tej populaciji bolnikov zaradi pomanjkanja podatkov sicer ni mogoče dati, vendar je treba razmisliti o zmanjšanju odmerka in/ali podaljšanju intervala med odmerki, sorazmerno zmanjšanju pri odraslih.
What you need to know before you take Zerit
Kaj morate vedeti, preden boste vzeli zdravilo Zerit
Stavudine was genotoxic in in vitro tests in human lymphocytes possessing triphosphorylating activity (in which no no-effect level was established), in mouse fibroblasts, and in an in vivo test for chromosomal aberrations.
Stavudin je bil genotoksičen v preizkusih in vitro v človeških limfocitih s trifosforilacijsko aktivnostjo (pri katerih niso ugotovili "ravni brez učinka" [no-effect level]), v mišjih fibroblastih ter v in vivo preizkusu za kromosomske aberacije.
common: depression uncommon: anxiety, emotional lability
pogosti: depresija občasni: anksioznost, čustvena labilnost
Contact your doctor or pharmacist for advice.
Za nasvet se obrnite na zdravnika ali farmacevta.
hepatic steatosis (fat in the liver)
jetrna steatoza (čezmerno kopičenje maščobe v jetrih)
The duration of therapy with Zerit should be limited to the shortest time possible (see section 4.2).
Zdravljenje z zdravilom Zerit je treba omejiti na najkrajši možen čas (glejte poglavje 4.2).
The apparent volume of distribution at steady state is 46±21 l. It was not possible to detect stavudine in cerebrospinal fluid until at least 2 hours after oral administration.
Navidezni volumen porazdelitve v stanju dinamičnega ravnovesja je 46 ± 21 l. V cerebrospinalnem likvorju je bilo mogoče stavudin odkriti šele najmanj 2 uri po peroralni uporabi.
Macrocytosis was not evaluated in these trials, but was found to be associated with Zerit in an earlier trial (MCV > 112 fl occurred in 30% of patients treated with Zerit).
Makrocitoze v teh raziskavah niso ocenjevali, vendar je bilo v eni od prejšnjih raziskav ugotovljeno, da je povezana z zdravilom Zerit (MCV > 112 fl se je pojavil pri 30% bolnikov, ki so dobivali zdravilo Zerit).
In the rare cases when this is inappropriate, dose reduction of stavudine may be considered, while the symptoms of peripheral neuropathy are under close monitoring and satisfactory virological suppression is maintained.
V redkih primerih, v katerih to ni primerno, se lahko razmisli o zmanjšanju odmerka stavudina, pri čemer je treba zagotoviti skrben nadzor nad simptomi periferne nevropatije in zagotoviti zadovoljivo zaviranje razmnoževanja virusa.
Caution should be exercised when administering stavudine to any patient (particularly obese women) with hepatomegaly, hepatitis or other known risk factors for liver disease and hepatic steatosis (including certain medicinal products and alcohol).
Previdnost je potrebna med uporabo stavudina pri bolnikih (predvsem pri ženskah s prekomerno telesno težo) s hepatomegalijo, hepatitisom ali drugimi znanimi dejavniki tveganja za bolezni jeter ali steatozo jeter (vključno z določenimi zdravili in alkoholom).
Pancreatitis, occasionally fatal, has been reported in up to 2-3% of patients enrolled in monotherapy clinical studies (see section 4.4).
Pankreatitis, ki je bil v nekaterih primerih usoden, so opisali pri 2 do 3% bolnikov, vključenih v klinične študije z monoterapijo (glejte poglavje 4.4).
Patients were primarily males (76%) and white (66%) with a median age of 34 years (range 22 to 67 years).
Bolniki so bili večinoma moškega spola (76%) in belci (66%), njihova srednja starost pa je bila 34 let (razpon od 22 do 67 let).
Prepare the ready-to-use solution by mixing the powder with 202 ml of water or by slowly adding water up to the top edge of the bottle label shown by the arrow fill marks.
Raztopino pripravite za uporabo tako, da prašek zmešate z 202 ml vode, ali s počasnim dolivanjem vode do zgornjega roba nalepke na plastenki, kot je označeno s puščicami.
This product contains methylhydroxybenzoate (E218) and propylhydroxybenzoate (E216) that may cause allergic reactions (possibly delayed).
Zdravilo vsebuje metilparahidroksibenzoat (E218) in propilparahidroksibenzoat (E216), ki lahko povzročita alergijske reakcije (lahko zapoznele).
The incidence and severity of lipoatrophy are related to cumulative exposure, and is often not reversible when stavudine treatment is stopped.
Pojavnost in izrazitost lipoatrofije sta odvisni od kumulativne izpostavljenosti, ki ob prekinitvi zdravljenja s stavudinom pogosto ni reverzibilna.
There have been reports of mitochondrial dysfunction in HIV-negative infants exposed in utero and/or post-natally to nucleoside analogues (see also section 4.8); these have predominantly concerned treatment with regimens containing zidovudine.
Obstajajo poročila o mitohondrijski disfunkciji pri HIV-negativnih dojenčkih, ki so bili in utero in/ali postnatalno izpostavljeni nukleozidnim analogom (glejte tudi poglavje 4.8); ta zadevajo predvsem zdravljenje z režimi, ki vključujejo zidovudin.
The bottle should be shaken well, until the powder dissolves completely.
Plastenko dobro pretresite, dokler se prašek povsem ne raztopi.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Preobčutljivost za zdravilno učinkovino ali katero koli pomožno snov navedeno v poglavju 6.1.
Stavudine does not inhibit the major cytochrome P450 isoforms CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4; therefore, it is unlikely that clinically significant drug interactions will occur with medicines metabolised through these pathways.
Stavudin ne zavira glavnih izooblik citokroma P450 CYP1A2, CYP2C9, CYP2C19, CYP2D6 in CYP3A4, zato ni verjetno, da bi se pojavile klinično pomembne interakcije z zdravili, ki se presnavljajo po teh poteh.
PHARMACEUTICAL FORM AND CONTENTS Powder for oral solution, 200 mg
FARMACEVTSKA OBLIKA IN VSEBINA prašek za peroralno raztopino, 200 mg
No clinically relevant pharmacokinetic interaction has, however, been seen with lamivudine.
Ni pa ugotovljenih klinično pomembnih farmakokinetičnih interakcij z lamivudinom.
Stavudine's influence on the phosphorylation kinetics of nucleoside analogues other than zidovudine has not been investigated.
Vpliv stavudina na fosforilacijsko kinetiko drugih nukleozidnih analogov razen zidovudina ni raziskan.
Patients continuing treatment with Zerit should be assessed frequently and switched to an alternative appropriate therapy whenever possible (see section 4.4).
Bolnike, ki nadaljujejo zdravljenje z zdravilom Zerit, je treba pogosto nadzirati in zdravljenje takoj, ko je mogoče, zamenjati z ustreznim alternativnim zdravljenjem (glejte poglavje 4.4).
A rat study also showed placental transfer of stavudine, with the foetal tissue concentration approximately 50% of the maternal plasma concentration.
Raziskava na podganah je prav tako pokazala prehajanje stavudina skozi placento; v plodovih tkivih je zdravilo doseglo koncentracijo, ki je znašala približno 50% koncentracije v materini plazmi.
In addition, rare cases of liver failure/renal failure or fatal hepatitis have been reported.
Poleg tega so bili opisani redki primeri odpovedi jeter/odpovedi ledvic in usodnega hepatitisa.
If you stop taking Zerit The decision to stop using Zerit should be discussed with your doctor.
Če ste prenehali jemati zdravilo Zerit O prenehanju jemanja zdravila Zerit se morate posvetovati s svojim zdravnikom.
Apparent oral clearance was approximately 14 ml/min/kg for infants ages 5 weeks to 15 years, 12 ml/min/kg for infants ages 14 to 28 days, and 5 ml/min/kg for infants on the day of birth.
Navidezni peroralni očistek je bil približno 14 ml/min/kg pri otrocih, starih od 5 tednov do 15 let, 12 ml/min/kg pri dojenčkih, starih od 14 do 28 dni, in 5 ml/min/kg pri dojenčkih na dan rojstva.
Do not store above 30°C (HDPE bottles).
Shranjujte pri temperaturi do 30°C (HDPE plastenke).
Relevant grade 3-4 laboratory abnormalities in the 91 stavudine treated infants were low neutrophils in 7%, low hemoglobin in 1%, ALT increase in 1% and no lipase abnormality.
Pomembne laboratorijske nenormalnosti 3. do 4. stopnje pri 91 dojenčkih, zdravljenih s stavudinom so bile: majhno število nevtrofilcev pri 7%, nizek hemoglobin pri 1% in zvišanje ALT pri 1%; nenormalnosti lipaze ni bilo.
Keep the bottle tightly closed in order to protect from excessive moisture.
Plastenko shranjujte tesno zaprto za zagotovitev zaščite pred vlago.
uncommon: arthralgia, myalgia
občasni: artralgija, mialgija
Patients should be monitored for symptoms (persistent numbness, tingling or pain in feet/hands) and if present patients should be switched to an alternate treatment regimen (see section 4.2 and Not recommended combinations, below).
Pri bolnikih je treba spremljati simptome (dolgotrajna omrtvelost, mravljinčenje ali bolečina v stopalih ali dlaneh) in v primeru njihove prisotnosti zamenjati način zdravljenja (glejte poglavje 4.2 in Nepriporočljive kombinacije, spodaj).
To reconsistute Zerit, add 202 ml of water to the original bottle (when the patient makes up the solution, they should be instructed to fill to the top edge of the bottle label, indicated by the arrow marks).
Pri raztapljanju zdravila Zerit v originalno plastenko dodajte 202 ml vode (če raztopino pripravlja bolnik, mu je treba naročiti, naj napolni plastenko do zgornjega roba nalepke, kjer je oznaka s puščicami).
Zerit should be reconstituted with water to a 200 ml deliverable volume solution (stavudine concentration of 1 mg/ml).
Zdravilo Zerit raztopite z vodo, da dobite 200 ml uporabne količine raztopine (koncentracija stavudina 1 mg/ml).
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
Pri otrocih katerih matere so med nosečnostjo jemale nukleozidne in nukleotidne zaviralce reverzne transkriptaze (NRTIs) je korist zaščite pred virusom HIV odtehtala tveganje za neželene učinke.
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
Pri nekaterih bolnikih z napredovalo okužbo s HIV (AIDS) in z oportunistično okužbo v anamnezi se lahko kmalu po začetku anti-HIV zdravljenja pojavijo znaki in simptomi vnetja povezani s prejšnjimi okužbami.
In vitro studies indicate that the activation of stavudine is inhibited by doxorubicin and ribavirin but not by other medicinal products used in HIV infection which are similarly phosphorylated, (e.g. didanosine, zalcitabine, ganciclovir and foscarnet) therefore, coadministration of stavudine with either doxorubicin or ribavirin should be undertaken with caution.
Študije in vitro kažejo, da aktiviranje stavudina zavirata doksorubicin in ribavirin, ne pa druga zdravila, ki se uporabljajo proti okužbi s HIV in se podobno fosforilirajo (npr. didanozin, zalcitabin, ganciklovir in foskarnet), zato je pri sočasnem dajanju stavudina in bodisi doksorubicina ali ribavirina potrebna previdnost.
Hepatic impairment: stavudine pharmacokinetics in patients with hepatic impairment were similar to those in patients with normal hepatic function.
Okvara jeter: farmakokinetika stavudina pri bolnikih z okvaro jeter je bila podobna kot pri bolnikih z normalnim delovanjem jeter.
Zerit may also be administered by carefully opening the hard capsule and mixing the contents with food.
Bolnik lahko zdravilo Zerit jemlje tudi tako, da trdo kapsulo previdno odpre in njeno vsebino zmeša s hrano.
If you are affected, do not drive and do not use any tools or machines.
V teh primerih ne smete voziti vozil in upravljati z orodji ali s stroji.
Adolescents, children and infants: the recommended oral dosage is
Mladostniki, otroci in dojenčki: Priporočeno odmerjanje pri peroralni uporabi je
Clinically significant interactions of stavudine or stavudine plus didanosine with nelfinavir have not been observed.
Klinično pomembnih interakcij stavudina ali stavudina in didanozina z nelfinavirom niso opažali.
Do not use this medicine after the expiry date which is stated on the carton, the bottle label and/or the blister after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatlici, nalepki plastenke in/ali pretisnem omotu poleg oznake "EXP".
The therapy should be initiated by a doctor experienced in the management of HIV infection (see also section 4.4).
Zdravljenje mora začeti zdravnik, ki ima izkušnje z zdravljenjem okužbe s HIV (glejte tudi poglavje 4.4).
Preclinical studies showed placental transfer of stavudine (see section 5.3).
Predklinične raziskave kažejo, da stavudin prehaja skozi placento (glejte poglavje 5.3).
HIV RNA < 400 copies/ml, treatment response, % All patients
Vrednost HIV RNA < 400 kopij/ml, odziv zdravljenja, % Vsi bolniki
Until additional data become available, Zerit should be given during pregnancy only after special consideration; there is insufficient information to recommend Zerit for prevention of mother-to-child transmission of HIV.
Dokler ni na voljo dodatnih podatkov, se sme zdravilo Zerit med nosečnostjo uporabljati le po posebnem razmisleku; informacij, na podlagi katerih bi lahko zdravilo Zerit priporočili za preprečevanje prenosa HIV z matere na otroka, ni dovolj.
Some patients taking Zerit may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
Pri nekaterih bolnikih, ki se zdravijo z zdravilom Zerit, se lahko pojavi bolezen kosti, imenovana osteonekroza (odmiranje kostnega tkiva zaradi nezadostne prekrvitve kosti).
HIV RNA < 50 copies/ml, treatment response, % All patients
Vrednost HIV RNA < 50 kopij/ml, odziv zdravljenja, % Vsi bolniki
Four hours after administration, the CSF/plasma ratio was 0.39±0.06.
Štiri ure po uporabi je razmerje med cerebrospinalno tekočino in plazmo 0,39 ± 0,06.
Adult patients that have problems swallowing capsules should ask their doctor about the possibility of changing to the powder formulation of this medicine.
Odrasli bolniki, ki imajo težave s požiranjem kapsul, se morajo s svojim zdravnikom posvetovati o možnosti uporabe tega zdravila v obliki praška za peroralno raztopino.
OTHER SPECIAL WARNING(S), IF NECESSARY Shake well before use.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Pred uporabo dobro pretresite!
Zerit can cause a sometimes fatal condition called lactic acidosis, together with an enlarged liver.
Zdravilo Zerit lahko povzroči včasih usodno stanje, imenovano laktacidoza, in hkratno povečanje jeter.
After multiple oral administration of 0.5-0.67 mg/kg doses, a Cmax value of 810±175 ng/ml was obtained.
Po večkratnem zaužitju odmerkov 0,5-0,67 mg/kg je bila dosežena vrednost Cmax 810 ± 175 ng/ml.
PHARMACEUTICAL FORM AND CONTENTS 56 hard capsules
FARMACEVTSKA OBLIKA IN VSEBINA 56 trdih kapsul
Two to three hours post-dose, CSF/plasma ratios of stavudine ranged from 16% to 125% (mean of 59%±35%).
Od dve do tri ure po odmerku je bilo razmerje med stavudinom v cerebrospinalnem likvorju in plazmi od 16 do 125% (srednja vrednost: 59% ± 35%).
Do not use this medicine after the expiry date which is stated on the bottle and on the carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatlici poleg oznake "EXP".
Osteonecrosis: cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART).
Osteonekroza: opisani so bili primeri osteonekroze, še zlasti pri bolnikih s splošno znanimi dejavniki tveganja, napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART).
The corresponding values after oral single and multiple dose administration are 35% (range: 8% to 72%) and 40% (range: 12% to 82%), respectively.
Ustrezne vrednosti po enkratnem peroralnem odmerku so 35% (razpon: od 8% do 72%), po ponavljajočih se peroralnih odmerkih pa 40% (razpon: od 12% do 82%).
Patients receiving Zerit should be frequently examined and questioned for signs of lipoatrophy.
Bolnike je treba med zdravljenjem z zdravilom Zerit redno ocenjevati in povprašati glede znakov lipoatrofije.
Patients were primarily males (70%) and non-white (58%) with a median age of 33 years (range 18 to 68 years).
Bolniki so bili večinoma moškega spola (70%) in nebelci (58%), njihova srednja starost pa je bila 33 let (razpon od 18 do 68 let).
Complications of chronic overdosage could include peripheral neuropathy and hepatic dysfunction.
Med zapleti kroničnega prevelikega odmerjanja bi lahko bili periferna nevropatija in moteno delovanje jeter.
Since stavudine is actively secreted by the renal tubules, interactions with other actively secreted medicinal products are possible, e.g. with trimethoprim.
Stavudin se aktivno izloča v ledvičnih tubulih, zato so možne interakcije z drugimi zdravili, ki se tudi aktivno izločajo, npr. s trimetoprimom.
Zidovudine and stavudine are phosphorylated by the cellular enzyme (thymidine kinase), which preferentially phosphorylates zidovudine, thereby decreasing the phosphorylation of stavudine to its active triphosphate form.
Fosforilacija zidovudina in stavudina poteka s celičnim encimom (timidin-kinazo), ki prednostno fosforilira zidovudin, tako da se zmanjša fosforilacija stavudina v njegovo aktivno trifosfatno obliko.
Adults: the recommended oral dosage is
Odrasli: Priporočeno odmerjanje pri peroralni uporabi je
Zerit belongs to a particular group of antiviral medicines, also known as antiretrovirals, called nucleoside reverse transcriptase inhibitors (NRTIs).
Zdravilo Zerit spada v podskupino protivirusnih zdravil, znanih tudi kot protiretrovirusna zdravila, ki jih imenujemo nukleozidni in nukleotidni zaviralci reverzne transkriptaze (NRTIs, “nucleoside reverse transcriptase inhibitors”).
* Patients on haemodialysis should take Zerit after the completion of haemodialysis, and at the same time on non-dialysis days.
* Bolniki na hemodializi naj zdravilo Zerit vzamejo po koncu hemodialize, v dneh, ko nimajo dialize, pa ob istem času.
Given these potential risks, a benefit-risk assessment for each patient should be made and an alternative antiretroviral should be carefully considered (see section 4.4 and below).
Zaradi teh možnih tveganj je potrebno pri vsakem bolniku oceniti koristi in tveganja ter natančno razmisliti o drugem protiretrovirusnem zdravljenju (glejte poglavje 4.4 in spodaj).
If you are allergic to stavudine or any of the other ingredients of this medicine (listed in section 6).
Ne jemljite zdravila Zerit če ste alergični na zdravilno učinkovino ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Peripheral neuropathy was seen in combination studies of Zerit with lamivudine plus efavirenz; the frequency of peripheral neurologic symptoms was 19% (6% for moderate to severe) with a rate of discontinuation due to neuropathy of 2%.
Periferno nevropatijo so opazili v študijah, v katerih so zdravilo Zerit uporabljali v kombinaciji z lamivudinom in efavirenzom; pogostnost perifernih nevroloških simptomov je bila 19% (6% zmernih do hudih), delež prekinitev zaradi nevropatije je bil 2%.
It is recommended that HIV-infected women should not breast-feed under any circumstances in order to avoid transmission of HIV to the baby.
Priporočljivo je, da s HIV okužene ženske pod nobenim pogojem ne dojijo, da ne bi prišlo do prenosa HIV na otroka.
Before reconstitution the Zerit powder appears as off-white to pale-pink, gritty powder.
Pred rekonstitucijo je Zerit prašek sivobel do bledo rožnat zrnat prašek.
Treatment with stavudine (Zerit) often causes a loss of fat from legs, arms and face (lipoatrophy).
Zdravljenje s stavudinom (Zerit) pogosto povzroča izginotje maščobnega tkiva na nogah, rokah in obrazu (lipoatrofija).
The clinical relevance of these findings suggest that stavudine should be generally avoided in the presence of TAMs, especially M41L and T215Y.
Klinični pomen teh ugotovitev je, da se je v primeru prisotnosti mutacije timidinskih analogov, še posebej v primeru M41L in T215Y, treba običajno izogniti uporabi stavudina.
The HIV status for the newborns and infants ≤ 3 months of age was negative, for older infants it tended to be positive.
Novorojenčki in dojenčki stari ≤ 3 mesece so bili HIV-negativni, starejši dojenčki pa so bili praviloma pozitivni.
In the event of rapidly elevating transaminase levels (ALT/AST, > 5 times upper limit of normal, ULN), discontinuation of Zerit and any potentially hepatotoxic medicinal products should be considered.
Če raven transaminaz hitro poraste (ALT/AST > 5-kratna zgornja normalna meja, (ZNM)), je treba razmisliti o prenehanju uporabe zdravila Zerit in morebitnih drugih hepatotoksičnih zdravil.
Late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour).
Redko so poročali o primerih nevroloških motenj, ki nastopijo kasneje (hipertonija, konvulzije, nenormalno obnašanje).
When reconstituted with 202 ml of water, produces 210 ml of a colorless to slightly pink, hazy solution.
Po dodajanju 202 ml vode dobimo 210 ml brezbarvne do rahlo rožnate motne raztopine.
Cellular DNA polymerase γ is also sensitive to inhibition by stavudine triphosphate, while cellular polymerases α and β are inhibited at concentrations 4,000-fold and 40-fold higher, respectively, than that needed to inhibit HIV reverse transcriptase.
Na zavrtje s stavudintrifosfatom je občutljiva tudi celična DNA-polimeraza γ, medtem ko je za zavrtje celične polimeraze α potrebna 4.000-krat večja, za zavrtje celične polimeraze β pa 40-krat večja koncentracija kot za zavrtje reverzne transkriptaze HIV.
Pancreatitis: patients with a history of pancreatitis had an incidence of approximately 5% onZerit, as compared to approximately 2% in patients without such a history.
Pankreatitis: Pri bolnikih z anamnezo pankreatitisa je incidenca med uporabo zdravila Zerit približno 5%, pri bolnikih brez takšne anamneze pa približno 2%.
During treatment, other infections linked to a weakened immunity (opportunistic infections) may arise.
Med zdravljenjem se lahko pojavijo druge okužbe (oportunistične okužbe), povezane z oslabelo imunostjo.
Do not take Zerit if you are taking didanosine, used to treat HIV infection.
Ne jemljite zdravila Zerit, če jemljete didanozin, ki se uporablja za zdravljenje okužbe z virusom HIV.
Zerit contains sucrose and preservatives
Zdravilo Zerit vsebuje saharozo in konzervanse
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Pri bolnikih z že obstoječo disfunkcijo jeter (s kroničnim aktivnim hepatitisom vred) se med kombiniranim protiretrovirusnim zdravljenjem pogosteje pojavljajo nepravilnosti v delovanju jeter, zato jih je treba nadzirati v skladu s standardno prakso.
Treatment naive pregnant women were enrolled into the study at gestation week 34-36 and given antiretroviral treatment until delivery.
V raziskavo so vključili nosečnice v obdobju od 34. do 36. gestacijskega tedna, ki še niso bile zdravljene s protiretrovirusnimi zdravili in so do poroda dobivale protiretrovirusno zdravljenje.
Children from birth to 13 days old should receive 0.5 mg/kg twice daily.
Otroci od rojstva do 13. dne starosti morajo dobivati 0,5 mg/kg dvakrat na dan.